Tu-Liang Liang

机构：Guangzhou University of Chinese Medicine, Shenzhen Pingle Orthopedic Hospital

发表论文 15 篇 · 总被引 468 次 · h-index 8

代表论文

• Metabolomics and integrated network pharmacology analysis reveal Tricin as the active anti-cancer component of Weijing decoction by suppression of PRKCA and sphingolipid signaling (2021 · Pharmacological Research · 被引 105)
• The key role of sphingolipid metabolism in cancer: New therapeutic targets, diagnostic and prognostic values, and anti-tumor immunotherapy resistance (2022 · Frontiers in Oncology · 被引 92)
• Andrographolide suppresses non-small-cell lung cancer progression through induction of autophagy and antitumor immune response (2022 · Pharmacological Research · 被引 90)
• Emodin induces apoptosis and suppresses non-small-cell lung cancer growth via downregulation of sPLA2-IIa (2021 · Phytomedicine · 被引 62)
• Immunometabolism and oxidative stress: roles and therapeutic strategies in cancer and aging (2025 · npj Aging · 被引 32)
• CERS4 predicts positive anti-PD-1 response and promotes immunomodulation through Rhob-mediated suppression of CD8+Tim3+ exhausted T cells in non-small cell lung cancer (2023 · Pharmacological Research · 被引 23)